Next Article in Journal
Protective Effect of Anthocyanin from Lonicera Caerulea var. Edulis on Radiation-Induced Damage in Mice
Next Article in Special Issue
Mechanisms of Oxidative Damage in Multiple Sclerosis and Neurodegenerative Diseases: Therapeutic Modulation via Fumaric Acid Esters
Previous Article in Journal
Environmental Risk Factors for Multiple Sclerosis: A Review with a Focus on Molecular Mechanisms
Previous Article in Special Issue
Possible Alterations in β-Synuclein, the Non-Amyloidogenic Homologue of α-Synuclein, during Progression of Sporadic α-Synucleinopathies
Int. J. Mol. Sci. 2012, 13(9), 11753-11772; doi:10.3390/ijms130911753

Neuroprotection for Stroke: Current Status and Future Perspectives

1,2,†,* , 3,†
, 3
 and 4
Received: 29 July 2012 / Revised: 6 September 2012 / Accepted: 7 September 2012 / Published: 18 September 2012
(This article belongs to the Special Issue Neuroprotective Strategies 2012)
View Full-Text   |   Download PDF [203 KB, uploaded 19 June 2014]
Abstract: Neuroprotection aims to prevent salvageable neurons from dying. Despite showing efficacy in experimental stroke studies, the concept of neuroprotection has failed in clinical trials. Reasons for the translational difficulties include a lack of methodological agreement between preclinical and clinical studies and the heterogeneity of stroke in humans compared to homogeneous strokes in animal models. Even when the international recommendations for preclinical stroke research, the Stroke Academic Industry Roundtable (STAIR) criteria, were followed, we have still seen limited success in the clinic, examples being NXY-059 and haematopoietic growth factors which fulfilled nearly all the STAIR criteria. However, there are a number of neuroprotective treatments under investigation in clinical trials such as hypothermia and ebselen. Moreover, promising neuroprotective treatments based on a deeper understanding of the complex pathophysiology of ischemic stroke such as inhibitors of NADPH oxidases and PSD-95 are currently evaluated in preclinical studies. Further concepts to improve translation include the investigation of neuroprotectants in multicenter preclinical Phase III-type studies, improved animal models, and close alignment between clinical trial and preclinical methodologies. Future successful translation will require both new concepts for preclinical testing and innovative approaches based on mechanistic insights into the ischemic cascade.
Keywords: neuroprotection; ischemic stroke; translation; STAIR; ischemic cascade neuroprotection; ischemic stroke; translation; STAIR; ischemic cascade
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |

MDPI and ACS Style

Minnerup, J.; Sutherland, B.A.; Buchan, A.M.; Kleinschnitz, C. Neuroprotection for Stroke: Current Status and Future Perspectives. Int. J. Mol. Sci. 2012, 13, 11753-11772.

AMA Style

Minnerup J, Sutherland BA, Buchan AM, Kleinschnitz C. Neuroprotection for Stroke: Current Status and Future Perspectives. International Journal of Molecular Sciences. 2012; 13(9):11753-11772.

Chicago/Turabian Style

Minnerup, Jens; Sutherland, Brad A.; Buchan, Alastair M.; Kleinschnitz, Christoph. 2012. "Neuroprotection for Stroke: Current Status and Future Perspectives." Int. J. Mol. Sci. 13, no. 9: 11753-11772.

Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert